1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
652A81800BFE196328525841700383353
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-patient-advocacy-2020-optimizing-structure-function?OpenDocument
18
19OpenDocument
203.94.129.211
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Patient Advocacy

Patient Advocacy 2020: Optimizing the Structure of the Advocacy Function

ID: 5560


Features:

22 Info Graphics

8 Data Graphics

50+ Metrics

4 Narratives


Pages/Slides: 37


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Patient Advocacy 2020: Optimizing the Structure of the Advocacy Function"

STUDY OVERVIEW

Patient advocacy groups play a vital role in educating patients on new therapies and treatment options. Given their close relationship to patients, advocacy groups are critical partners for pharma as they seek to educate the public about new and existing therapies. The pharma function that works with patient advocacy groups has evolved as the industry seeks new and more effective ways to communicate with patient groups.

This research provides current benchmarks on the structure, staffing level, and communication processes that pharma advocacy groups are utilizing to increase their effectiveness. The study also contains a chapter that contains qualitative data from respondents regarding advocacy structure. Leaders who oversee the advocacy function within pharma can use this study to compare their metrics and structural approaches with their industry peers.


KEY TOPICS

  • Understanding the “Advocacy” landscape
  • Advocacy structures that work best
  • Advocacy staffing
  • Communicating with Advocacy Groups
  • Profiling Advocacy Group experience & expertise

SAMPLE KEY METRICS
  • Describe the structure of your company's patient advocacy function
  • Is your patient advocacy function's structure appropriate
  • How do you ensure that patient advocacy organizations can contact/communicate with your patient advocacy function personnel
  • Estimate the number of FTEs in your organization that are dedicated to patient advocacy activities
  • How many patient advocacy groups do you support
SAMPLE KEY FINDING
  • Steady rise in the number of advocacy groups supported by companies: Participating companies predict an increase in the number of external advocacy groups that their organization supports. Currently, companies have an average of 22 patient advocacy groups. In the coming two years, participants estimated they will support, on average, 27 patient advocacy groups. Meanwhile, companies have about 6 FTEs in their patient advocacy groups, on average. These employees have more than 9 years of advocacy experience, on average.

METHODOLOGY

This study engaged 74 leaders supporting patient advocacy at 61 life sciences companies and organizations. More than 60% of participants are at the director/ senior director level. Nearly 65% of participants are from the United States.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Communications; Medical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Clinical Research; Research; Health Care; Laboratories


Companies Profiled:
AbbVie; Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; ApotheCom; Astellas; AveXis; AVROBIO; Baldwin Area Medical Center; Bayer; Biogen; BioMarin; Bionical Emas; Blue Earth Diagnostics; Bluebird Bio; Boehringer Ingelheim; Covance; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Forum Pharmaceuticals; Grifols; GlaxoSmithKline ; Genzyme; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Lundbeck; Mallinckrodt; Merck; Milestone Pharmaceuticals; MSD; Natera; NexGen Healthcare Communications; Novartis; Novo Nordisk; OTSUKA; Parkway Pantai; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Sanofi; Servier; Shire; Spark Therapeutics; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; Theravance; Tillotts Pharma; UCB Pharma; Ultragenyx; Wave Life Sciences; Zimmer Biomet; Zogenix; The Mexican Organization for Rare Disorders (OMER)

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.